Integrated safety and efficacy of garadacimab for hereditary angioedema prophylaxis across 3 clinical trials: phase 2, pivotal phase 3, and open- label extension studies

被引：0
|
作者：
Magerl, M. [1 ,2 ]
Craig, T. J. [3 ]
Anderson, J. [4 ]
Jacobs, J. S. [5 ]
Tachdjian, R. [6 ]
Farkas, H. [7 ]
Yang, W. H. [8 ]
Staubach, P. [9 ]
Aygoeren-Puersuen, E. [10 ]
Ohsawa, I. [11 ]
Pollen, M. [12 ]
Lawo, J. -P. [13 ]
Bica, M. A. [13 ]
Jacobs, I. [12 ]
机构：
[1] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
[2] Fraunhofer Inst Translat Med & Pharmacol ITMP Immu, Berlin, Germany
[3] Penn State Univ, Dept Med & Pediat, Allergy Asthma & Immunol, Hershey, PA USA
[4] AllerVie Clin Res, Birmingham, AL USA
[5] Allergy & Asthma Clin Res, Walnut Creek, CA USA
[6] Univ Calif Los Angeles, Div Allergy & Clin Immunol, David Geffen Sch Med, Los Angeles, CA USA
[7] Semmelweis Univ, Hungarian Angioedema Ctr Reference & Excellence, Dept Internal Med & Haematol, Budapest, Hungary
[8] Univ Ottawa, Ottawa Allergy Res Corp, Ottawa, ON, Canada
[9] Univ Med Ctr Mainz, Dept Dermatol & Allergy, Mainz, Germany
[10] Univ Hosp Frankfurt, Dept Children & Adolescents, Frankfurt, Germany
[11] Saiyu Soka Hosp, Dept Nephrol, Saitama, Japan
[12] CSL Behring, King Of Prussia, PA USA
[13] CSL Behring Innovat GmbH, Marburg, Germany
来源：
ALLERGOLOGIE | 2024年 / 47卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P2.9
引用
收藏
页数：55
相关论文
共 50 条
  • [31] Safety patterns with ozanimod in phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. P.
    Singal, M.
    Thorpe, A.
    Riolo, J. V.
    Cheng, C. Y.
    Sheffield, J. K.
    Krakovich, A.
    Vermersch, P.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 324 - 324
  • [32] Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3
    Lumry, William R.
    Farkas, Henriette
    Moldovan, Dumitru
    Toubi, Elias
    Baptista, Jovanna
    Craig, Timothy
    Riedl, Marc
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2015, 168 (01) : 44 - 55
  • [33] Efficacy and Safety of Lanadelumab in pediatric Patients with hereditary Angioedema aged 2 to < 12 Years: Results of the open-label, multi-centric Phase 3 SPRING Study
    Kappek, M.
    Maurer, M.
    Lumry, W. R.
    Li, H. H.
    Aygoeren-Pursun, E.
    Busse, P.
    Jacobs, J.
    Nurse, C.
    ALLERGOLOGIE, 2023, 46 (08) : 560 - 560
  • [34] Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
    Doody, RS
    Geldmacher, DS
    Gordon, B
    Perdomo, CA
    Pratt, RD
    ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 427 - 433
  • [35] TWO-YEAR ANALYSIS OF THE DONIDALORSEN PHASE 2 OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH HEREDITARY ANGIOEDEMA
    Cohn, D.
    Newman, K.
    Bordone, L.
    Deng, Y.
    Alexander, V.
    Dorow, S.
    Riedl, M.
    Schneider, E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S28 - S28
  • [36] An integrated efficacy and safety analysis of single-dose secnidazole 2 g granules in the treatment of bacterial vaginosis from pivotal phase 2 and phase 3 trials
    Pentikis, H. S.
    Adetoro, N.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 219 (06) : 647 - 648
  • [37] Phase 2 Open-Label Extension Study With Donidalorsen in Patients With Hereditary Angioedema: 1 Year Versus 2 Years
    Tachdjian, Raffi
    Bordone, Laura
    Dorow, Steve
    Cohn, Danny
    Schneider, Eugene
    Deng, Yiwen
    Newman, Kenneth
    Alexander, Veronica
    Riedl, Marc
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB11 - AB11
  • [38] Efficacy of Bempedoic Acid: A Pooled Analysis of 4 Pivotal Phase 3 Clinical Trials
    Banach, Maciej
    Duell, P. Barton
    Gotto, Antonio
    Laufs, Ulrich
    Leiter, Lawrence A.
    Mancini, G. B. J.
    Ray, Kausik K.
    Flaim, JoAnn
    Ye, Zhan
    Catapano, Alberico L.
    CIRCULATION, 2019, 140
  • [39] Efficacy of bempedoic acid: A pooled analysis of 4 pivotal phase 3 clinical trials
    Laufs, Ulrich
    Banach, Maciej
    Duell, P. Barton
    Gotto, Antonio
    Leiter, Lawrence A.
    Mancini, G. B. John
    Ray, Kausik K.
    Louie, Michael J.
    Ye, Zhan
    Catapano, Alberico L.
    INTERNIST, 2021, 62 (SUPPL 2): : 171 - 171
  • [40] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. -P.
    Singal, M.
    Riolo, J. V.
    Cheng, C. -Y.
    Sheffield, J. K.
    Minton, N.
    Vermersch, P.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
12345